Delivery Order SPE2DB22D2005-SPE2DB25FJSB3
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $4,998.29 to AmerisourceBergen Drug Corp for the supply of Nayzilam 5 mg nasal spray, with an ultimate completion date of August 8, 2025. This firm fixed price, non-set-aside delivery order is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to federal military and healthcare systems. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Nayzilam 5 mg nasal sprays under a firm fixed-price contract valued at $1,043.25, with an ultimate completion date of July 31, 2025. This non-set-aside contract represents a small-value transaction within AmerisourceBergen's broader pharmaceutical supply relationship with DLA. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a $2,086.50 delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Nayzilam 5 mg nasal sprays. This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 22, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order operates under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency's Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $1,043.25 for Nayzilam 5 mg nasal sprays on July 29, 2025, with completion scheduled for July 30, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's Conshohocken, Pennsylvania facility. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Nayzilam 5 mg nasal sprays, with a ceiling value of $1,043.25. This is a firm fixed price, competitively awarded contract with no set-aside designation. The delivery order is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 30, 2025. This award represents a child contract under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Nayzilam 5 mg nasal sprays, with a ceiling value of $1,043.25. This is a firm fixed-price delivery order with an ultimate completion date of July 30, 2025, and represents no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical federal medical procurement vendor. The order...
- The Defense Logistics Agency awarded a delivery order valued at $1,391.00 to AmerisourceBergen Drug Corp for the supply of Nayzilam 5 mg nasal spray. This firm fixed price contract, awarded on August 12, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The delivery order carries no set-aside designation and will be performed at AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $1,043.25 to AmerisourceBergen Drug Corp for Nayzilam 5 mg nasal sprays. The contract was competitively awarded without set-aside provisions and carries a firm fixed price structure with an ultimate completion date of August 12, 2025. This delivery order is being fulfilled from AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Nayzilam 5 mg nasal sprays. The contract has a firm fixed price, with a ceiling value of $2,434.06, and a period of performance through May 6, 2025. The contract is not set aside for any specific type of business. AmerisourceBergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Nayzilam 5 mg nasal sprays, with a ceiling value of $2,371.57 and an ultimate completion date of August 15, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The award leverages AmerisourceBergen's established relationship with the federal government as a major pharmaceutical distributor serving military and veteran healthcare systems. The place...
- SPE2DB22D2005Indefinite Delivery Contract
- SPE2DB22D2005-SPE2DB25FJSB3Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Nayzilam 5 mg nasal spray, valued at $2,086.50, with an ultimate completion date of August 20, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award and reflects the agency's pharmaceutical procurement through its established medical supply chain. The product will be delivered to the company's facility in Conshohocken, Pennsylvania. This delivery order is executed under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.99 billion and extending through December 2026. This prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling the contractor to supply a broad range of pharmaceutical products, medical supplies, vaccines, and specialized medical commodities to support military healthcare programs worldwide. AmerisourceBergen Drug Corp's consistent performance in competitively awarded federal pharmaceutical contracts demonstrates its capability to fulfill critical medical supply requirements for the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.1k | 8/19/25 |